🇺🇸 FDA
Patent

US 11638761

Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11638761 (Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy) held by Dyne Therapeutics, Inc. expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K38/00, A61K47/6807